IL0011407140
© Globe Newswire
05.12.2025
URGN
LISTED
NASDAQ
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
PRINCETON, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 14 new employees in connection with their employment with...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2025
URGN
LISTED
NASDAQ
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
News Preview
PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the Piper Sandler 37th Annual Healthcare Conference to take place on December 2-4, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
URGN
LISTED
NASDAQ
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
News Preview
PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the third quarter ended September 30, 2025, and provided an overview of recent developments....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
02.10.2025
URGN
LISTED
NASDAQ
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
News Preview
Reviews in Urology literature review of ZUSDURI (UNG-102) clinical trial program including ENVISION, OPTIMA II and the ATLAS clinical trials...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
07.08.2025
URGN
LISTED
NASDAQ
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results
News Preview
PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the second quarter ended June 30, 2025, and provided an overview of recent developments....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.07.2025
URGN
LISTED
NASDAQ
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025
News Preview
Conference Call and Webcast Scheduled for Thursday, August 7th, 2025, at 10:00 AM ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.07.2025
URGN
LISTED
NASDAQ
UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
News Preview
PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions for urothelial and specialty cancers, today announced the publication of results of a five-year long-term extension study of the Phase 2b OPTIMA II trial evaluating ZUSDURI (mitom...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.07.2025
URGN
LISTED
NASDAQ
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
News Preview
PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has completed patient enrollment in its Phase 3 UTOPIA clinical trial of UGN-103 (mitomycin) for intravesical...
Themefolio
Profiler
Peergroup
© BusinessWire
12.06.2025
URGN
LISTED
NASDAQ
U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the U.S. Food and Drug Administration (FDA) approved ZUSDURI, the first and only FDA-approved medication for adults with recurrent LG-IR-NMIBC. ZUSDURI consists of mitomy...
Themefolio
Profiler
Peergroup
© BusinessWire
06.06.2025
URGN
LISTED
NASDAQ
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 27 new employees in connection with their employment with UroGen. These new team members will support the ongo...
Themefolio
Profiler
Peergroup
© BusinessWire
05.06.2025
URGN
LISTED
NASDAQ
URGN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, both dates inclusive (the “Class Period”), have until July 28, 2025 to seek appointment as lead plaintiff of the UroGen class action lawsuit. Captioned Cockrell v. UroGe...
Themefolio
Profiler
Peergroup
© BusinessWire
03.06.2025
URGN
LISTED
NASDAQ
Rosen Law Firm Urges UroGen Pharma Ltd. (NASDAQ: URGN) Stockholders With Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of UroGen Pharms Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, both dates inclusive (the “Class Period”). UroGen engages in the development and commercialization of solutions fo...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
03.06.2025
URGN
LISTED
NASDAQ
Law Offices of Frank R. Cruz Encourages UroGen Pharma Ltd. (URGN) Investors To Inquire About Securities Fraud Class Action
News Preview
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”). UroGen investors have until July 28, 2025 to file a lead plaintiff motion.
IF Y...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
URGN
LISTED
NASDAQ
Deadline Approaching: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
News Preview
Law Offices of Howard G. Smith reminds investors of the upcoming July 28, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”).
IF YOU ARE AN INVESTOR WHO...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
URGN
LISTED
NASDAQ
UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the presentation of the uTRACT Registry study design at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. The uTRACT Registry is a single-a...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
URGN
LISTED
NASDAQ
UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from the ENVISION and ATLAS clinical studies exploring investigational therapy UGN-102 (mitomycin) for intravesical solution for the treatment for recurrent low-g...
Themefolio
Profiler
Peergroup
© BusinessWire
31.05.2025
URGN
LISTED
NASDAQ
URGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, both dates inclusive (the “Class Period”), have until July 28, 2025 to seek appointment as lead plaintiff of the UroGen class action lawsuit. Captioned Cockrell v. UroGe...
Themefolio
Profiler
Peergroup
© BusinessWire
31.05.2025
URGN
LISTED
NASDAQ
URGN ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of UroGen Pharma Ltd. Investors
News Preview
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of those who acquired UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ:URGN) securities during the period from July 27, 2023, through May 15, 2025 (“the Class Period”). Investors have un...
Themefolio
Profiler
Peergroup
© BusinessWire
30.05.2025
URGN
LISTED
NASDAQ
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against UroGen Pharma Ltd. (“UroGen” or “the Company”) (NASDAQ: URGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Inve...
Themefolio
Profiler
Peergroup
© BusinessWire
30.05.2025
URGN
LISTED
NASDAQ
URGN BREAKING NEWS: UroGen Pharma Ltd. Stock Plummets 45% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:URGN)
News Preview
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the Company’s senior executives for potential violations of the federal securities laws.
If you invested in UroGen you are encouraged to obtain additional information by visiting https://www....
Themefolio
Profiler
Peergroup
© BusinessWire
30.05.2025
URGN
LISTED
NASDAQ
Deadline Alert: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
News Preview
Glancy Prongay & Murray LLP reminds investors of the upcoming July 28, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”)...
Themefolio
Profiler
Peergroup
© BusinessWire
29.05.2025
URGN
LISTED
NASDAQ
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) and reminds investors of the July 28, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi &...
Themefolio
Profiler
Peergroup
© BusinessWire
29.05.2025
URGN
LISTED
NASDAQ
Law Offices of Howard G. Smith Encourages UroGen Pharma Ltd. (URGN) Investors To Inquire About Securities Fraud Class Action
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”). UroGen investors have until July 28, 2025 to file a lead plaintiff motion.
IF YOU...
Themefolio
Profiler
Peergroup
© BusinessWire
29.05.2025
URGN
LISTED
NASDAQ
URGN CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against UroGen Pharma Ltd.
News Preview
The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the District of New Jersey, captioned Cockrell v. UroGen Pharma Ltd., et al., Case No. 3:25-cv-06088, on behalf of persons and entities that purchased or otherwise acquired UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASD...
Themefolio
Profiler
Peergroup
© BusinessWire
29.05.2025
URGN
LISTED
NASDAQ
URGN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit On Behalf Of UroGen Pharma Ltd. Investors
News Preview
Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the District of New Jersey, captioned Cockrell v. UroGen Pharma Ltd., et al., Case No. 3:25-cv-06088, on behalf of persons and entities that purchased or otherwise acquired UroGen Pharma Ltd. (“UroGen” or the “Company...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
URGN
LISTED
NASDAQ
UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a fireside chat at the TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA to take place on May 27-28, 2025.
TD Cow...
Themefolio
Profiler
Peergroup
© BusinessWire
21.05.2025
URGN
LISTED
NASDAQ
UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, announced the outcome of today’s meeting of the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA), which discussed the new drug application...
Themefolio
Profiler
Peergroup
© BusinessWire
19.05.2025
URGN
LISTED
NASDAQ
Securities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON UROGEN PH...
Themefolio
Profiler
Peergroup
© BusinessWire
19.05.2025
URGN
LISTED
NASDAQ
UroGen Pharma Ltd. (URGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN UROGEN PHARMA LTD. (URGN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALL...
Themefolio
Profiler
Peergroup
© BusinessWire
17.05.2025
URGN
LISTED
NASDAQ
Securities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
News Preview
The Law Offices of Frank R. Cruz announces an investigation of UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON UROGEN PHARMA LTD. (URGN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO...
Themefolio
Profiler
Peergroup
© BusinessWire
12.05.2025
URGN
LISTED
NASDAQ
UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2025, and provided an overview of recent developments.
“We are entering a pivotal and exciting period for UroGen...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
URGN
LISTED
NASDAQ
UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
News Preview
UroGen (NASDAQ: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the U.S. Food and Drug Administration (FDA) has scheduled an Oncologic Drugs Advisory Committee (ODAC) meeting on May 21, 2025 to review the new drug application (NDA) for UGN-1...
Themefolio
Profiler
Peergroup
© BusinessWire
01.05.2025
URGN
LISTED
NASDAQ
UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report first quarter 2025 financial results on Monday, May 12, 2025, prior to the open of the stock market. The announcement will be followed by a live audio...
Themefolio
Profiler
Peergroup
© BusinessWire
27.04.2025
URGN
LISTED
NASDAQ
OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights a duration of response of nearly four years from a long-term follow-up study with JELMYTO® (mitomycin) for pyelocalyceal solution, which is FDA-approved for the treatment of...
Themefolio
Profiler
Peergroup
© BusinessWire
27.04.2025
URGN
LISTED
NASDAQ
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced patient-reported outcomes following treatment of patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) that showed investigational dr...
Themefolio
Profiler
Peergroup
© BusinessWire
27.04.2025
URGN
LISTED
NASDAQ
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced new data from the OPTIMA II Phase 2b study of UGN‑102 (mitomycin) for intravesical solution demonstrate clinically meaningful two-year duration of response (24.2 months)...
Themefolio
Profiler
Peergroup
© BusinessWire
27.04.2025
URGN
LISTED
NASDAQ
UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced an updated 18-month DOR of 80.6% (95% CI: 74.0, 85.7), by Kaplan-Meier estimate, from the Phase 3 ENVISION trial of UGN-102 (mitomycin) for intravesical solution, an inve...
Themefolio
Profiler
Peergroup
© BusinessWire
26.04.2025
URGN
LISTED
NASDAQ
UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced encouraging safety data from the Phase 1 dose-escalation study for UGN-301 (zalifrelimab) intravesical solution, an investigational drug in development for the treatment...
Themefolio
Profiler
Peergroup
© BusinessWire
14.04.2025
URGN
LISTED
NASDAQ
UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that data on investigational drug UGN-102 (mitomycin) for intravesical solution, JELMYTO (mitomycin) for pyelocalyceal solution and UGN-301 (zalifrelimab) will be present...
Themefolio
Profiler
Peergroup
© BusinessWire
10.03.2025
URGN
LISTED
NASDAQ
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided an overview of recent developments.
“2024 was a pivotal year for UroGen with...
Themefolio
Profiler
Peergroup
© BusinessWire
07.03.2025
URGN
LISTED
NASDAQ
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 7 new employees in connection with their employment with UroGen. These new team members will support the ongoi...
Themefolio
Profiler
Peergroup
© BusinessWire
27.02.2025
URGN
LISTED
NASDAQ
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2024 financial results on Monday, March 10, 2025, prior to the open of the stock market. The announcement will be followe...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
URGN
LISTED
NASDAQ
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference to take place on March 3-5, 2025.
TD Cowen 45th Annual Health Care Confer...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
URGN
LISTED
NASDAQ
UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced expansion of its oncology pipeline portfolio through the acquisition of assets relating to a next-generation oncolytic virus ICVB-1042 from IconOVir Bio, Inc. (IconOVir)....
Themefolio
Profiler
Peergroup
© BusinessWire
14.02.2025
URGN
LISTED
NASDAQ
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from the subgroup analyses of the pivotal ENVISION study evaluating the impact of tumor burden and focality on the response to UGN-102, an investigational drug in...
Themefolio
Profiler
Peergroup
© BusinessWire
12.02.2025
URGN
LISTED
NASDAQ
Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights results from a long-term follow-up study with JELMYTO® (mitomycin) for pyelocalyceal solution, which is FDA approved for the treatment of low-grade, upper tract urothelial ca...
Themefolio
Profiler
Peergroup
© BusinessWire
30.01.2025
URGN
LISTED
NASDAQ
UroGen Pharma to Present at Upcoming Investor Conferences
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate at the following investor conferences in February:
Guggenheim Securities SMID Cap Biotech Conference
Date / Time:
February 5, 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
15.01.2025
URGN
LISTED
NASDAQ
ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the 3-month complete response (CR) rate and 12-month durability of response from the Phase 3 ENVISION study of investigational drug UGN-102 in patients with low-grad...
Themefolio
Profiler
Peergroup
© BusinessWire
06.12.2024
URGN
LISTED
NASDAQ
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 35 new employees in connection with their employment with UroGen. These new team members will support the ongo...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2024
URGN
LISTED
NASDAQ
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights results from a long-term follow-up study with JELMYTO (mitomycin) for pyelocalyceal solution, which is FDA approved for the treatment of adults with low-grade, upper tra...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2024
URGN
LISTED
NASDAQ
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the presentation of the Phase 3 ENVISION trial’s efficacy and safety results at the Society of Urologic Oncology (SUO) annual meeting in Dallas, TX. These results, publis...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2024
URGN
LISTED
NASDAQ
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that new data on UGN-102 (mitomycin) for intravesical solution, JELMYTO (mitomycin) for pyelocalyceal solution, and UGN-301(zalifrelimab intravesical solution) will be pr...
Themefolio
Profiler
Peergroup
© BusinessWire
26.11.2024
URGN
LISTED
NASDAQ
New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights results from a long-term follow-up study with JELMYTO (mitomycin) for pyelocalyceal solution, which is FDA approved for the treatment of low-grade, upper tract urothelial can...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
URGN
LISTED
NASDAQ
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the third quarter ended September 30, 2024, and provided an overview of recent developments.
“The recent FDA acceptance of our New Drug Application...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
URGN
LISTED
NASDAQ
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
News Preview
UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will participate in a fireside chat at the Guggenheim Securities Healthcare Innovation Conference to take place November 11-13, 2024.
Guggenheim Securitie...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
URGN
LISTED
NASDAQ
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
News Preview
UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report 2024 third quarter financial results on Wednesday, November 6, 2024, prior to the open of the stock market. The announcement will be followed by a live...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2024
URGN
LISTED
NASDAQ
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that new long-term durability of response results from the Phase 3 ENVISION study of investigational drug UGN-102 in patients with low-grade intermediate-risk non-muscle-...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2024
URGN
LISTED
NASDAQ
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for investigational drug UGN-102 (mitomycin) for intravesical solution. UGN-102 could...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2024
URGN
LISTED
NASDAQ
UroGen Appoints Chris Degnan as Chief Financial Officer
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that Chris Degnan has been appointed Chief Financial Officer. Mr. Degnan succeeds Don Kim, who is leaving UroGen to pursue other opportunities.
"Under Don's financial st...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2024
URGN
LISTED
NASDAQ
First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
News Preview
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the first patient was dosed in the Phase 3 clinical trial of investigational drug UGN-103 (mitomycin) for intravesical solution in development for the treatment of l...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
